We're excited to join the hematology community at #ASH26! Explore the data we'll be presenting and follow along for updates from the meeting. bit.ly/3WgK2aJ
Incyte
Verified account This account is verified because it's an official organization on X. Learn more@Incyte
Incyte’s official Twitter. Ready to Solve On. See our Community Guidelines: bit.ly/2sV0H5W
140 Following 6.8K Followers 2.1K Posts
Latest posts 5
Read our press release to learn about our Q3 financial results and business updates, including progress across our portfolio. bit.ly/3UTF7Mo
0:10
Learn more from Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development, on the progress being made across our GI oncology portfolio at #ESMO26. bit.ly/4yDiOs9
0:15
Incyte shared new data from our KRAS G12D and TGFβR2xPD-1 programs in PDAC and MSS CRC at #ESMO26. Learn more. bit.ly/3WMBt7v
0:10
Despite advances, pancreatic ductal adenocarcinoma (PDAC) remains one of the most challenging cancers to treat.
Understanding KRAS G12D mutations is central to advancing more targeted research for these patients. Learn more. #SolveOn bit.ly/4iaUDfX
Understanding KRAS G12D mutations is central to advancing more targeted research for these patients. Learn more. #SolveOn bit.ly/4iaUDfX
